ABUS (Arbutus Biopharma) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Arbutus Biopharma Days Payable?

Arbutus Biopharma's average Accounts Payable for the three months ended in Sep. 2024 was $2.48 Mil. Arbutus Biopharma's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Arbutus Biopharma's Days Payable or its related term are showing as below:

ABUS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.14
* Ranked among companies with meaningful Days Payable only.

Arbutus Biopharma's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Arbutus Biopharma Days Payable Historical Data

The historical data trend for Arbutus Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Days Payable Chart

Arbutus Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Arbutus Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Arbutus Biopharma's Days Payable

For the Biotechnology subindustry, Arbutus Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Days Payable falls into.

Arbutus Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Arbutus Biopharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (3.52	+	3.223)	/	2 )	/	0	*	365
=	3.3715					/	0	*	365
=	N/A

Arbutus Biopharma's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (2.652	+	2.315)	/	2 )	/	0	*	365 / 4
=	2.4835					/	0	*	365 / 4
=	N/A

Arbutus Biopharma Days Payable Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (NAS:ABUS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

0SGC:UK I9DN:Germany I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Executives

Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Karen Sims	officer: Chief Medical Officer	701 VETERANS CIRCLE, WARMINSTER PA 18974
David C Hastings	officer: Chief Financial Officer	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Michael J. Mcelhaugh	officer: Chief Business Officer	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Michael J. Sofia	officer: Chief Scientific Officer	C/O ARBUTUS BIOPHARMA CORP., SUITE 100, 8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Melissa Rewolinski	director	9000 STATE ROAD, PHILADELPHIA PA 19136
J. Christopher Naftzger	officer: General Counsel and CCO	633 LOWTHER ROAD, LEWISBERRY PA 17339
Tram Tran	director	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
James R Meyers	director	GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew Cheng	director	170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
William H. Collier	director, officer: President and CEO	C/O ARBUTUS BIOPHARMA CORPORATION, 701 VETERANS CIRCLE, WARMINSTER PA 18974
Elizabeth Howard	officer: Executive VP & General Counsel	100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8